In rodent models of T2DM, TRPV4 agonists promote vasodilation and improve cardiovascular function, whereas TRPV4 antagonists reduce HFD-induced obesity, insulin resistance, DN, retinopathy and neuropathy (Ref. The gene discussed is TRPV4; the disease is type 2 diabetes mellitus.